Table 3.

Hazard ratios for developing Kaposi Sarcoma among HIV-infected patients in South Africa from multivariable Cox models.

		Model 1	Model 2	Model 3
		HR (95% CI)	HR (95% CI)	HR (95% CI)
Patients included [total/KS cases]		17,890 / 148	17,890 / 148	17,890 / 148
Time-updated ART	Not on ART	1	1	1
	On ART	0.22 (0.15 – 0.32)	0.22 (0.15 – 0.32)	0.19 (0.13 – 0.28)
Gender	Female	-	1	1
	Male	-	1.99 (1.43 – 2.77)	1.88 (1.35 – 2.62)
Age at baseline [years]	16 – 29	-	1	1
	30 – 39	-	1.14 (0.75 – 1.74)	1.13 (0.75 – 1.73)
	40 – 49	-	0.89 (0.53 – 1.49)	0.89 (0.53 – 1.48)
	≥ 50	-	1.13 (0.59 – 2.17)	1.16 (0.60 – 2.23)
Time-updated CD4 cell count [cells/μL]	< 50	-	-	1
	50 – 99	-	-	0.61 (0.37 – 0.99)
	100 – 349	-	-	0.46 (0.31 – 0.68)
	≥ 350	-	-	0.35 (0.16 – 0.76)

ART, antiretroviral therapy; KS, Kaposi Sarcoma. All models were stratified by cohort and include only patients with complete information for ART status, age, gender and CD4 cell counts. Age at baseline refers to age at enrolment into the cohort plus 30 days in patients not on ART and to start of ART plus 30 days in patients on ART.

We adjusted models for time-updated ART (model 1), plus gender and age (model 2), plus time-updated CD4 cell counts (model 3)